20 assets in Ovarian Carcinosarcoma

Therapeutic assets addressing Ovarian Carcinosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Ovarian Carcinosarcoma	Mayo Clinic	P2	BB (64)
Adriamycin Ovarian Carcinosarcoma	National Cancer Institute (NCI)	P2	B (60)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Ovarian Carcinosarcoma	Mayo Clinic	P2	B (60)
Pembrolizumab Ovarian Carcinosarcoma	Mayo Clinic	P2	B (60)
Dostarlimab Ovarian Carcinosarcoma	ARCAGY/ GINECO GROUP	P2/3	B (57)
Niraparib Ovarian Carcinosarcoma	ARCAGY/ GINECO GROUP	P2/3	B (57)
Adsorbed Purified Pertussis Vaccine Ovarian Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Ovarian Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Adsorbed Ovarian Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Fludarabine Ovarian Carcinosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Ovarian Carcinosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Ovarian Carcinosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Ovarian Carcinosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Pegcetacoplan Ovarian Carcinosarcoma	Roswell Park Cancer Institute	P2	CCC (53)
Tetanus Toxoid Ovarian Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Adavosertib Ovarian Carcinosarcoma	National Cancer Institute (NCI)	P2	CCC (52)
Vls-1488 Ovarian Carcinosarcoma	Volastra Therapeutics, Inc.	P1/2	CCC (48)
Tolinapant Ovarian Carcinosarcoma	National Cancer Institute (NCI)	P1/2	CC (46)
Autologous Muc1-Activated T-Cells Ovarian Carcinosarcoma	Mayo Clinic	P1	CC (43)
Bendamustine Ovarian Carcinosarcoma	Mayo Clinic	P1	CC (43)